Stephens Inc. AR Sells 48 Shares of Veeva Systems Inc. (NYSE:VEEV)

Stephens Inc. AR decreased its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 2.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,740 shares of the technology company’s stock after selling 48 shares during the quarter. Stephens Inc. AR’s holdings in Veeva Systems were worth $366,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in VEEV. NBC Securities Inc. increased its position in shares of Veeva Systems by 8.4% during the third quarter. NBC Securities Inc. now owns 1,347 shares of the technology company’s stock valued at $282,000 after buying an additional 104 shares during the period. Bleakley Financial Group LLC increased its holdings in Veeva Systems by 11.0% during the 3rd quarter. Bleakley Financial Group LLC now owns 4,476 shares of the technology company’s stock worth $939,000 after acquiring an additional 445 shares during the period. Net Worth Advisory Group bought a new stake in Veeva Systems during the 3rd quarter worth approximately $520,000. Blue Trust Inc. increased its holdings in Veeva Systems by 453.9% during the 3rd quarter. Blue Trust Inc. now owns 986 shares of the technology company’s stock worth $207,000 after acquiring an additional 808 shares during the period. Finally, Slow Capital Inc. increased its holdings in Veeva Systems by 0.7% during the 3rd quarter. Slow Capital Inc. now owns 12,234 shares of the technology company’s stock worth $2,568,000 after acquiring an additional 80 shares during the period. Institutional investors own 88.20% of the company’s stock.

Veeva Systems Stock Down 0.0 %

Shares of VEEV opened at $234.09 on Friday. The stock has a market capitalization of $38.00 billion, a P/E ratio of 57.80, a PEG ratio of 1.97 and a beta of 0.85. Veeva Systems Inc. has a twelve month low of $170.25 and a twelve month high of $258.93. The firm has a fifty day simple moving average of $224.48 and a two-hundred day simple moving average of $215.96.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on VEEV shares. Robert W. Baird upped their target price on shares of Veeva Systems from $275.00 to $283.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Citigroup upped their target price on shares of Veeva Systems from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Mizuho started coverage on shares of Veeva Systems in a report on Wednesday, December 4th. They set an “outperform” rating and a $275.00 target price on the stock. Morgan Stanley upped their target price on shares of Veeva Systems from $183.00 to $195.00 and gave the stock an “underweight” rating in a report on Tuesday, December 17th. Finally, Bank of America increased their price target on shares of Veeva Systems from $280.00 to $290.00 and gave the stock a “neutral” rating in a report on Friday, December 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $253.96.

Insider Activity

In other news, SVP Jonathan Faddis sold 1,694 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $230.30, for a total transaction of $390,128.20. Following the sale, the senior vice president now owns 8,061 shares of the company’s stock, valued at $1,856,448.30. This trade represents a 17.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.50% of the company’s stock.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.